NCT07288359 2026-02-23
Study of GVV858 as a Single Agent or in Combination With Endocrine Therapy in Patients With HR+/HER2- Breast Cancer and Other Advanced Solid Tumors
Novartis
Phase 1/2 Recruiting
Novartis
OHSU Knight Cancer Institute
Pfizer
OHSU Knight Cancer Institute
Massachusetts General Hospital